Results

1–5 of 5 results for John A. Wells

Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Updates from the Field
2025
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024
Protocol T Extension Results
John A. Wells, MD, FACS
Updates from the Field
2019
Diabetic Retinopathy Part II Take-Home Panel
John A. Wells, MD, FACS
Annual Meeting Talks